retatrutide type 2 diabetes phase 2 results 2024 ada shows substantial weight loss, glycemic control in obesity and | 2026 ADA26: retatrutide delivers unprecedented weight

By 48 weeks, the gap widens to 24.2% versus approximately 18-19%

Participants received orforglipron at doses of 6, 12, or 36 mg (which correspond to the current 5.5, 14.5, and 17.2 mg maintenance doses) or placebo, alongside diet and exercise counselling, for 72 weeks

For more severe nausea or vomiting, doctors may prescribe ondansetron (Zofran)

I know that some people havent been able to eat as much, but I still have a pretty interesting appetite

To understand where this compound fits in the broader history of these molecules, you can read our comprehensive GLP-1 class overview

Measurements of waist, hips, chest, arms, thighs